Effect of Memantine on Prolonging Safe Driving in Early AD: a Pilot Study

Authors

  • Peter J. Holland Florida Atlantic University
  • Ruth M. Tappen Florida Atlantic University https://orcid.org/0000-0002-2122-8173
  • David O. Newman Florida Atlantic University
  • Katherine C. Freeman-Costin Florida Atlantic University
  • Lori J. Fisher Florida Atlantic University

DOI:

https://doi.org/10.5770/cgj.24.540

Keywords:

dementia, driving, Alzheimer’s disease, memantine, feasibility, survival time

Abstract

 Background 

To determine the feasibility of conducting an RCT on the potential effectiveness of memantine hydrochloride in prolonging safe driving in mild AD. 

Methods 

A placebo-controlled, double blind randomized trial was conducted. Forty-three individuals ≥60 with mild AD met screening criteria and were randomized. Driving ability was measured by a standardized on-road driving test. Outcomes were driving capacity at 6 and 12 months and completion of the 12-month intervention. 

Results 

Of 43 participants randomized, 59% of the memantine group and 52% of the placebo group completed the on-road test at 12 months (p = .66). All 13 memantine group participants maintained their driving status at 12 months, whereas only 8 of the 11 placebo group participants did (p = .040, OR = 4.45). 

Conclusions 

Results provide the framework for designing a rigorous multisite clinical trial of memantine effect on maintaining driving capacity in mild AD. 

Downloads

Download data is not yet available.

Downloads

Published

2021-12-01

How to Cite

1.
Holland PJ, Tappen RM, Newman DO, Freeman-Costin KC, Fisher LJ. Effect of Memantine on Prolonging Safe Driving in Early AD: a Pilot Study. Can Geriatr J [Internet]. 2021 Dec. 1 [cited 2022 Jan. 26];24(4):292-6. Available from: https://cgjonline.ca/index.php/cgj/article/view/540

Issue

Section

Original Research